These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27669306)

  • 1. Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma.
    Bann DV; Deschler DG; Goyal N
    Cancers (Basel); 2016 Sep; 8(10):. PubMed ID: 27669306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
    Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
    Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects.
    Gao L; Zhang A; Yang F; Du W
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines.
    Sun Z; Sun X; Chen Z; Du J; Wu Y
    Int J Pept Res Ther; 2022; 28(1):19. PubMed ID: 34903958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy: The future of cancer treatment.
    Sahu M; Suryawanshi H
    J Oral Maxillofac Pathol; 2021; 25(2):371. PubMed ID: 34703141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review).
    Wei C; Lan X; Qiu M; Cui R; Fu Q; Shinge SAU; Muluh TA; Jiang O
    Oncol Lett; 2023 Sep; 26(3):372. PubMed ID: 37965160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical immunotherapeutic approaches for the treatment of head and neck cancer.
    Kareemaghay S; Tavassoli M
    Int J Oral Maxillofac Surg; 2019 Apr; 48(4):419-436. PubMed ID: 30401512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma.
    Liu S; Wang R; Fang J
    Discov Oncol; 2024 Jan; 15(1):22. PubMed ID: 38294629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic Approaches to Head and Neck Cancer.
    Nasser H; St John M
    Crit Rev Oncog; 2018; 23(3-4):161-171. PubMed ID: 30311572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promise of immunotherapy in head and neck squamous cell carcinoma.
    Economopoulou P; Agelaki S; Perisanidis C; Giotakis EI; Psyrri A
    Ann Oncol; 2016 Sep; 27(9):1675-85. PubMed ID: 27380958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma.
    Yu C; Li Q; Zhang Y; Wen ZF; Dong H; Mou Y
    Front Cell Dev Biol; 2022; 10():941750. PubMed ID: 36092724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges.
    Orland MD; Ullah F; Yilmaz E; Geiger JL
    JCO Oncol Pract; 2024 May; ():OP2400041. PubMed ID: 38709998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapies for head and neck squamous cell carcinomas].
    Yan XJ; Xu KL; Zhang XX
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jul; 31(13):1050-1056. PubMed ID: 29798179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
    Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
    Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.
    Economopoulou P; Kotsantis I; Psyrri A
    ESMO Open; 2016; 1(6):e000122. PubMed ID: 28848660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
    Azoury SC; Gilmore RC; Shukla V
    Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Taberna M; Oliva M; Mesía R
    Front Oncol; 2019; 9():383. PubMed ID: 31165040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Human Papilloma Virus and Risk Factors among Patients with Head and Neck Squamous Cell Carcinoma Attending a Tertiary Referral Centre in South India.
    Bandhary SK; Shetty V; Saldanha M; Gatti P; Devegowda D; R PS; Shetty AK
    Asian Pac J Cancer Prev; 2018 May; 19(5):1325-1330. PubMed ID: 29802694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.